Treatment Costs and Social Burden of Pancreatic Cancer

Abstract

(1) Background: Pancreatic cancer is the cancer with the third-highest mortality rate, and forecasts indicate its growing share in morbidity. The basis of treatment is inpatient chemotherapy and there is a strong focus on palliative care. (2) Methods: A literature review was conducted based on the rapid review methodology in PubMed and Cochrane databases. The search was supplemented with publications from the snowball search. Qualitative assessment of included publications was performed using AMSTAR2 modified scheme. (3) Results: The review included 17 publications, of which majority concerned direct costs related to the adopted treatment regimen. Most of the publications focused on comparing the cost-effectiveness of drug therapies and the costs of palliative treatment. Other publications concerned indirect costs generated by pancreatic cancer. They particularly focused on the economic burden of lost productivity due to sickness absence. (4) Conclusion: The increase in the incidence of pancreatic cancer translates into an increase in the costs of the health care system and indirect costs. Due to the significant share of hospitalization in the health care structure, direct costs are increasing. The inpatient treatment regimen and side effects translate into a loss of productivity for patients with pancreatic cancer. Among gastrointestinal cancers, pancreatic cancer generates the second largest indirect costs, although it has a much lower incidence rate than the dominant colorectal cancer. This indicates a significant problem of the economic burden of this cancer.

How a significant increase in survival in pancreatic cancer is achieved. The role of nutritional status and supportive care: A review

“…При этом экономическое положение страны и развитость системы здравоохранения, а также возможность покрытия медицинских расходов на лечение пациентов вносят свой вклад в показатели выживаемости. Так, среди онкозаболеваний желудочно-кишечного тракта (ЖКТ) РПЖ является вторым по затратам, хотя уровень заболеваемости РПЖ гораздо ниже, чем у лидирующего в списке колоректального рака [25]. Это свидетельствует о значительном экономическом бремени, которое возлагает РПЖ на системы здравоохранения.…”

Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer

“…Direct non-medical costs, such as specialised dietary supplements, transportation, accommodation, and informal nursing, also can quickly accumulate and thus pose significant challenges for patients with limited financial resources [ 3 , 5 , 6 ]. Additionally, indirect costs related to the impact of the illness on patients’ ability to earn income and caregivers’ lost productivity further compound the economic burden associated with cancer [ 3 , 4 , 6 ]. Extended periods of unemployment can have a severe financial impact on patients and their families [ 8 ].…”